Table 1 The combination molecules on Tregs of targeted drugs in clinical trials
Targets | drugs | Cancer type | NCT |
|---|---|---|---|
CD25 | Basiliximab | T-Cell and NK-Cell Non-Hodgkin Lymphoma | NCT02342782 |
Basiliximab | Recurrent Adult Hodgkin Lymphoma | NCT01476839 | |
Daclizumab | Hodgkin Lymphoma | NCT01468311 | |
Daclizumab | Melanoma | NCT00847106 | |
CTLA-4 | Tremelimumab | Cutaneous Melanoma | NCT04274816 |
Tremelimumab | Malignant Mesothelioma | NCT01655888 | |
Tremelimumab | Colorectal Neoplasms Melanoma Prostatic Neoplasms Renal Cell Carcinoma Neoplasms Patients Who Have/Have Had Tumors | NCT00378482 | |
Tremelimumab | Malignant Mesothelioma | NCT01649024 | |
Ipilimumab | Melanoma | NCT02027935 | |
Ipilimumab | Prostate Cancer | NCT01804465 | |
Ipilimumab | HNSCC | NCT04080804 | |
Ipilimumab | Sarcoma Wilm’s Tumor Lymphoma Neuroblastoma | NCT01445379 | |
Ipilimumab | Melanoma | NCT00972933 | |
Ipilimumab | Pancreatic Cancer | NCT00112580 | |
Ipilimumab | Extensive Stage Small Cell Lung Cancer | NCT01331525 | |
CP-675,206 | HCC | NCT01008358 | |
CP-675,206 | Melanoma | NCT00431275 | |
BCD-145 | Melanoma | NCT03472027 | |
ADU-1604 | Metastatic Melanoma | NCT03674502 | |
GITR | MK-4166 | Glioblastoma | NCT03707457 |
BMS-986156 | MetastaticMalignant Solid Neoplasm | NCT04021043 | |
GWN323 | Solid Tumors Lymphomas | NCT02740270 | |
TRX518 | Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies | NCT01239134 | |
LAG-3 | Sym022 | Metastatic Cancer Solid Tumor Lymphoma | NCT03489369 |
anti-LAG-3 | Multiple Myeloma Relapsed Refractory Multiple Myeloma | NCT04150965 | |
anti-LAG-3 | Microsatellite Unstable Colorectal Cancer Microsatellite Stable Colorectal Cancer Mismatch Repair Proficient Colorectal Cancer Mismatch Repair Deficient Colorectal Cancer | NCT02060188 | |
BMS-986016 | Glioblastoma Recurrent Brain Neoplasm | NCT02658981 | |
BMS-986016 | Hematologic Neoplasms | NCT02061761 | |
Relatlimab | •Neoplasms by Site | NCT01968109 | |
Relatlimab | HNSCC | NCT04080804 | |
Relatlimab | Gastroesophageal Cancer | NCT03610711 | |
Relatlimab | Chordoma Locally Advanced Chordoma Metastatic Chordoma Unresectable Chordoma | NCT03623854 | |
Relatlimab | Various Advanced Cancer | NCT02488759 | |
Relatlimab | Advanced Cancer | NCT03459222 | |
Relatlimab | Melanoma | NCT03743766 | |
Relatlimab | Cancer | NCT02966548 | |
Relatlimab | Gastric Cancer Esophageal Cancer GastroEsophageal Cancer | NCT03044613 | |
Relatlimab | Microsatellite Stable (MSS) Colorectal Adenocarcinomas Colorectal Adenocarcinoma | NCT03642067 | |
REGN3767 | Malignancies | NCT03005782 | |
Sym022 | Metastatic Cancer Solid Tumor Lymphoma | NCT03311412 | |
TSR-033 | Advanced or Metastatic Solid Tumors | NCT02817633 | |
TSR-033 | Advanced Solid Tumors Antibodies Immunotherapy Colorectal Cancer | NCT03250832 | |
BMS-986213 | Gastric Cancer Cancer of the Stomach Esophagogastric Junction | NCT03662659 | |
TIGIT | BGB-A1217 | Metastatic Solid Tumors | NCT04047862 |
MTIG7192A | Non-small Cell Lung Cancer | NCT03563716 | |
Tiragolumab | Small Cell Lung Cancer | NCT04256421 | |
Tiragolumab | Non-Small Cell Lung Cancer | NCT04294810 | |
OX40 | anti-OX40 | Head and Neck Cancer | NCT02274155 |
anti-OX40 | Advanced Cancer | NCT01644968 | |
anti-OX40 | Metastatic Prostate Cancer Cancer of the Prostate Prostate Cancer | NCT01303705 | |
PF-04518600 | Clear Cell Renal Cell Carcinoma Metastatic Renal Cell Cancer Recurrent Renal Cell Carcinoma Stage IV Renal Cell Cancer | NCT03092856 | |
PF-04518600 | Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Invasive Breast Carcinoma Recurrent Breast Carcinoma Triple-Negative Breast Carcinoma | NCT03971409 | |
PF-04518600 | Advanced Malignant Solid Neoplasm Castration-Resistant Prostate Carcinoma Malignant Neoplasm Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Metastatic Prostate Carcinoma Prostate Carcinoma Metastatic in the Bone Refractory Malignant Solid Neoplasm Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 | NCT03217747 | |
PF-04518600 | Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia | NCT03390296 | |
MEDI6469 | Colorectal Neoplasms | NCT02559024 | |
MEDI6469 | Metastatic Breast Cancer Lung Metastases Liver Metastases | NCT01862900 | |
BMS 986178 | B-Cell Non-Hodgkin Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma | NCT03410901 | |
BMS 986178 | Advanced Malignant Solid Neoplasm Extracranial Solid Neoplasm Metastatic Malignant Solid Neoplasm | NCT03831295 | |
MOXR0916 | Neoplasms | NCT02410512 | |
BGB-A445 | Advanced Solid Tumor | NCT04215978 | |
ICOS | MEDI-570 | Follicular T-Cell Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent Angioimmunoblastic T-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | NCT02520791 |
KY1044 | Squamous Cell Carcinoma of Head and Neck Non-small Cell Lung Cancer Hepatocellular Carcinoma Esophageal Cancer Gastric Cancer Melanoma Renal Cell Carcinoma Pancreatic Cancer Cervical Cancer Triple Negative Breast Cancer Advanced Cancer | NCT03829501 | |
CCR4 | Mogamulizumab | Stage IB-IIB Cutaneous T-Cell Lymphoma | NCT04128072 |
Mogamulizumab | Gastric Cancer Esophageal Cancer Lung Cancer Renal Cancer Oral Cancer | NCT02946671 | |
KW-0761 | Cutaneous T-Cell Lymphoma | NCT01728805 | |
KW-0761 | Adult T-cell Leukemia-Lymphoma | NCT01626664 | |
KW-0761 | Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma | NCT01226472 | |
KW-0761 | Peripheral T-Cell Lymphoma | NCT01611142 | |
KW-0761 | Peripheral T-Cell Lymphoma | NCT00888927 |